Report cover image

Neuroendocrine Tumors Drug Pipeline Analysis Report 2025

Publisher Expert Market Research
Published May 25, 2025
Length 200 Pages
SKU # EMAR20146989

Description

Neuroendocrine tumors affect about 35 out of every 100,000 people globally, whereas the incidence is thought to affect about 6 out of every 100,000 people annually. There has been an increase in the number of cases in the United States with more than six times the growth between 1973 and 2012, mainly because of increased awareness about the disease and better diagnostic facilities. Several companies are engaged in research initiatives which are boosting the drug landscape significantly.

Report Coverage

The Neuroendocrine Tumors Drug Pipeline Report by Expert Market Research gives comprehensive insights into neuroendocrine tumors drugs currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for neuroendocrine tumors. The report includes the analysis of over 50 pipeline drugs and 15+ companies. It will include an analysis based on efficacy and safety measure outcomes published for the trials including their adverse effects on patients suffering from neuroendocrine tumors.

The detailed analysis of each drug, drug class, clinical studies, phase type, molecule type, route of administration and ongoing neuroendocrine tumors pipeline development activities.

Neuroendocrine Tumors Drug Pipeline Outlook

Neuroendocrine cells combine the properties of nerve cells and hormone-producing endocrine cells. Neuroendocrine tumors occur due to uncontrolled cell growth which may be because of genetic mutations. Although NETs can occur anywhere in the body, the pancreas, gastrointestinal system, and the lungs are where they most frequently do. There is a correlation between an elevated risk of developing a certain type of NETs and certain inherited genetic disorders, such as multiple endocrine neoplasia type 1 (MEN1).

Upon the detection of tumor, surgery is considered the first line of neuroendocrine tumors treatment to remove the entire tumor. Targeted drugs, such as everolimus and somatostatin analogs are preferred for advanced or metastatic NETs. These therapies help manage the symptoms and decrease the growth of the tumor. Radiation therapy is often used to subside symptoms in incurable tumors, while chemotherapy is often used to treat aggressive malignancies. For some types of advanced NETs, peptide receptor radionuclide treatment (PRRT) proves to be beneficial. For instance, a trial is investigating the tolerability and efficacy of a drug that could be used in unresectable and locally advanced cancer. The presence of a large number of clinical trials for neuroendocrine tumors has influenced the pipeline landscape positively.

Neuroendocrine Tumors – Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of neuroendocrine tumor drug candidates based on several segmentations including:

By Phase

EMR’s pipeline assessment report covers 20+ drug analyses based on phase.
  • Late-Stage Products (Phase 3 and Phase 4)
  • Mid-Stage Products (Phase 2)
  • Early-Stage Products (Phase I)
  • Preclinical and Discovery Stage Products
By Molecule Type

EMR’s neuroendocrine tumors therapeutic assessment report covers 20+ drug analyses based on molecule type:
  • Recombinant Fusion Proteins
  • Small Molecule
  • Monoclonal Antibody
  • Peptides
  • Polymer
  • Gene Therapy
By Route of Administration

EMR’s pipeline assessment report covers 20+ drug analyses based on the route of administration.
  • Oral
  • Parenteral
  • Others
Neuroendocrine Tumors – Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II covers a major share of the total clinical trials for neuroendocrine tumors with around 18 pipeline drugs in phase II.

Neuroendocrine Tumors Pipeline Assessment Segmentation, By Drug Classes

The drug molecules categories covered under neuroendocrine tumors pipeline analysis includes recombinant fusion proteins, small molecules, monoclonal antibodies, peptides, polymer, and gene therapy. Several trials are ongoing to assess the efficacy of small molecules. Stud ies that targeted monoclonal antibodies have been highly effective in the management of neuroendocrine tumors. The report provides a comparative analysis of the molecule type for each molecule in various phases of clinical trials for neuroendocrine tumors.

Neuroendocrine Tumors Clinical Trials Assessment – Competitive Dynamics

The EMR report for the neuroendocrine tumors drug pipeline covers the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in neuroendocrine tumors clinical trials:
  • Novartis Pharmaceuticals
  • Provectus Biopharmaceuticals, Inc.
  • Hutchmed (China) Ltd
  • Camurus AB
  • Wren Laboratories LLC
  • TaiRx, Inc.
  • ITM Solucin GmbH
  • Ipsen SA
  • Radiomedix, Inc.
  • Sinotau Pharmaceutical Group
  • Clarity Pharmaceuticals Ltd
Neuroendocrine Tumors – Pipeline Drugs Profile

This section covers the detailed analysis of each drug under multiple phases including phase I, phase II, phase III, phase IV, and emerging drugs for neuroendocrine tumors. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of neuroendocrine tumors drug candidates.

Drug: Lutetium Oxodotreotide

The trial compares Lutetium [177Lu] Oxodotreotide Injection to high-dose Octreotide LAR in treating advanced gastroenteropancreatic neuroendocrine tumors. The trial is sponsored by Sinotau Pharmaceutical Group and is currently under phase III.

Drug: Lutetium Edotreotide

The study evaluates 177Lu-Edotreotide PRRT versus Everolimus in treating inoperable, progressive gastroenteric or pancreatic neuroendocrine tumors. The trial is sponsored by ITM Solucin GmbH and is currently under phase III.

Drug: Surufatinib

The trial evaluates the efficacy and tolerability of neuroendocrine tumors drug candidate Surufatinib in Japanese patients. The trial is sponsored by Hutchmed and is currently under phase II.

Reasons To Buy This Report

The Neuroendocrine Tumors Drug Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for neuroendocrine tumors. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into neuroendocrine tumors collaborations, regulatory environments, and potential growth opportunities within neuroendocrine tumors pipeline insights.

Key Questions Answered in the Neuroendocrine Tumors – Pipeline Assessment Report
  • Which companies/institutions are leading the neuroendocrine tumors drug development?
  • What is the efficacy and safety profile of neuroendocrine tumors pipeline drugs?
  • Which company is leading the neuroendocrine tumors pipeline development activities?
  • What is the current neuroendocrine tumors commercial assessment?
  • What are the opportunities and challenges present in the neuroendocrine tumors drug pipeline landscape?
  • What is the efficacy and safety profile of neuroendocrine tumors pipeline drugs?
  • Which company is conducting major trials for neuroendocrine tumors drugs?
  • Which companies/institutions are involved in neuroendocrine tumors collaborations aimed at providing enhanced therapeutic alternatives for patients?
  • What are the geographies covered for clinical trials in neuroendocrine tumors?
Related Reports

Neuroendocrine Tumours Treatment Market

Neuroendocrine Tumor Market

Global Clinical Trials Market

Table of Contents

200 Pages
1 Preface
1.1 Introduction
1.2 Objectives of the Study
1.3 Research Methodology & Assumptions
2 Executive Summary
3 Overview of Neuroendocrine Tumors Pipeline
3.1 Signs and Symptoms
3.2 Causes
3.3 Risk Factors
3.4 Diagnosis
3.5 Treatment
4 Patient Profile: Neuroendocrine Tumors Pipeline
4.1 Patient Profile Overview
4.2 Patient Psychology and Emotional Impact Factors
4.3 Risk Assessment and Treatment Success Rate
5 Neuroendocrine Tumors Pipeline: Epidemiology Snapshot
5.1 Neuroendocrine Tumors Pipeline Incidence by Key Markets
5.2 Neuroendocrine Tumors Pipeline – Patients Seeking Treatment in Key Markets
6 Neuroendocrine Tumors Pipeline: Market Dynamics
6.1 Market Drivers and Constraints
6.2 SWOT Analysis
7 Neuroendocrine Tumors Pipeline: Key Facts Covered
7.1 Top Countries Contributing to Clinical Trials in Asia-Pacific
7.2 Top Countries Contributing to Clinical Trials in Europe
7.3 Top Countries Contributing to Clinical Trials in North America
7.4 Top Countries Contributing to Clinical Trials in Other Regions
8 Neuroendocrine Tumors Pipeline, Drug Pipeline Assessment
8.1 Assessment by Treatment Type
8.2 Assessment by Route of Administration
8.3 Assessment by Drug Class
9 EMR Drug Pipeline Comparative Analysis
9.1 List of Neuroendocrine Tumors Pipeline Drugs
9.1.1 By Company
9.1.2 By Phase
9.1.3 By Indication
9.1.4 By Trial Status
9.1.5 By Funder Type
9.2 EMR Attribute Scoring Analysis of Pipeline Drugs (Top Drugs)
10 Neuroendocrine Tumors Drug Pipeline - Late-Stage Products (Phase III and IV) (Top Drugs)
10.1 Comparative Analysis for Late-Stage Drugs
10.1.1 Study Type
10.1.2 Recruitment Status
10.1.3 Company
10.1.4 Funder Type
10.2 Product Level Analysis*
10.2.1 Lutetium[177Lu] Oxodotreotide
10.2.1.1 Product Description
10.2.1.2 Trial ID
10.2.1.3 Sponsor Name
10.2.1.4 Study Type
10.2.1.5 Drug Class
10.2.1.6 Eligibility Criteria
10.2.1.7 Study Record Dates
10.2.1.7.1 First Submitted
10.2.1.7.2 First Posted
10.2.1.7.3 Last Update Posted
10.2.1.7.4 Last Verified
10.2.1.8 Indication
10.2.1.9 Study Design
10.2.1.10 Recruitment Status
10.2.1.11 Enrollment (Estimated)
10.2.1.12 Location Countries
10.2.1.13 Recent Results
10.2.2 177Lu-Edotreotide
10.2.3 Other Drugs
11 Neuroendocrine Tumors Drug Pipeline - Mid-Stage Products (Phase II) (Top Drugs)
11.1 Comparative Analysis for Mid-Stage Drugs
11.1.1 Study Type
11.1.2 Recruitment Status
11.1.3 Company
11.1.4 Funder Type
11.2 Product Level Analysis*
11.2.1 212Pb-Dotamtate
11.2.1.1 Product Description
11.2.1.2 Trial ID
11.2.1.3 Sponsor Name
11.2.1.4 Study Type
11.2.1.5 Drug Class
11.2.1.6 Eligibility Criteria
11.2.1.7 Study Record Dates
11.2.1.7.1 First Submitted
11.2.1.7.2 First Posted
11.2.1.7.3 Last Update Posted
11.2.1.7.4 Last Verified
11.2.1.8 Indication
11.2.1.9 Study Design
11.2.1.10 Recruitment Status
11.2.1.11 Enrollment (Estimated)
11.2.1.12 Location Countries
11.2.1.13 Recent Results
11.2.2 64Cu-Sartate
11.2.3 Other Drugs
12 Neuroendocrine Tumors Drug Pipeline - Early-Stage Products (Phase I) (Top Drugs)
12.1 Comparative Analysis for Early-Stage Drugs
12.1.1 Study Type
12.1.2 Recruitment Status
12.1.3 Company
12.1.4 Funder Type
12.2 Product Level Analysis*
12.2.1 Cabozantinib
12.2.1.1 Product Description
12.2.1.2 Trial ID
12.2.1.3 Sponsor Name
12.2.1.4 Study Type
12.2.1.5 Drug Class
12.2.1.6 Eligibility Criteria
12.2.1.7 Study Record Dates
12.2.1.7.1 First Submitted
12.2.1.7.2 First Posted
12.2.1.7.3 Last Update Posted
12.2.1.7.4 Last Verified
12.2.1.8 Indication
12.2.1.9 Study Design
12.2.1.10 Recruitment Status
12.2.1.11 Enrollment (Estimated)
12.2.1.12 Location Countries
12.2.2 18F-MFBG (Meta Fluorobenzyl Guanidine)
12.2.3 Other Drugs
13 Neuroendocrine Tumors Drug Pipeline - Preclinical and Discovery Stage Products (Top Drugs)
13.1 Comparative Analysis for Preclinical and Discovery Stage Drugs
13.1.1 Study Type
13.1.2 Recruitment Status
13.1.3 Company
13.1.4 Funder Type
13.2 Product Level Analysis*
13.2.1 Drug 1
13.2.1.1 Product Description
13.2.1.2 Trial ID
13.2.1.3 Sponsor Name
13.2.1.4 Study Type
13.2.1.5 Drug Class
13.2.1.6 Eligibility Criteria
13.2.1.7 Study Record Dates
13.2.1.7.1 First Submitted
13.2.1.7.2 First Posted
13.2.1.7.3 Last Update Posted
13.2.1.7.4 Last Verified
13.2.1.8 Indication
13.2.1.9 Study Design
13.2.1.10 Recruitment Status
13.2.1.11 Enrollment (Estimated)
13.2.1.12 Location Countries
13.2.2 Other Drugs
14 Neuroendocrine Tumors, Key Drug Pipeline Companies
14.1 Novartis Pharmaceuticals
14.1.1 Company Snapshot
14.1.2 Pipeline Product Portfolio
14.1.3 Financial Analysis
14.1.4 Recent News and Developments
14.2 Provectus Biopharmaceuticals, Inc.
14.2.1 Company Snapshot
14.2.2 Pipeline Product Portfolio
14.2.3 Financial Analysis
14.2.4 Recent News and Developments
14.3 Hutchmed (China) Ltd
14.3.1 Company Snapshot
14.3.2 Pipeline Product Portfolio
14.3.3 Financial Analysis
14.3.4 Recent News and Developments
14.4 Camurus AB
14.4.1 Company Snapshot
14.4.2 Pipeline Product Portfolio
14.4.3 Financial Analysis
14.4.4 Recent News and Developments
14.5 Wren Laboratories LLC
14.5.1 Company Snapshot
14.5.2 Pipeline Product Portfolio
14.5.3 Financial Analysis
14.5.4 Recent News and Developments
14.6 TaiRx, Inc.
14.6.1 Company Snapshot
14.6.2 Pipeline Product Portfolio
14.6.3 Financial Analysis
14.6.4 Recent News and Developments
14.7 ITM Solucin GmbH
14.7.1 Company Snapshot
14.7.2 Pipeline Product Portfolio
14.7.3 Financial Analysis
14.7.4 Recent News and Developments
15 Regulatory Framework for Drug Approval, By Region
16 Terminated or Suspended Pipeline Products

Pricing

Currency Rates
How Do Licenses Work?

How Do Licenses Work?

The primary function of a report license is to define how many people within a company are authorized to use the purchased report. This is separate to how a report might be delivered. Unless specifically identified otherwise, the purchase option is Single User. Below is a helpful description of that license, along with a sampling of others most commonly offered.

  • This license allows only one user to have access to and to use/read the report. It is not one user at a time or one user group; it is an individual who will be reading and utilizing the report.

  • This license allows for the entire purchasing company to read and use the report. This is the license level that would allow for a report to be placed on an internal company shared drive for access by all employees of that direct company. This license does not extend to parent or sister company use.

  • This license is designed to allow an entire department within a company full access to a report. The departmental license is a great option for companies that have more than one location and the department is spread out all over the country/world

  • This license is for companies that have one location where they want the report to be accessible by all employees within that physical location.

  • This is the most flexible of the licensing options. Some publishers will allow you to get a license for a preset number of people (typically 5). These licenses are ideal for small work groups.

License options are at the discretion of each publisher. As such, not all licenses indicated above are available for every product. If you are uncertain of the best license for your needs or would like a license that is not proactively available, please contact us and we will be happy to assist.

Head shot

Questions or Comments?

Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
Chat Now
Contact Us